-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Case Challenges in Myelofibrosis for the Community Clinician

Sponsor: CTI Biopharma Corp
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events, Study Population
Friday, December 8, 2023: 3:00 PM-6:00 PM
Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
Ruben A. Mesa, MD, ARRAY(0xf39c3d8)
Mesa: Abbvie: Research Funding; Incyte: Research Funding; Celgene: Research Funding; Genetech: Research Funding; Samus: Research Funding; Promedior: Research Funding; CTI BioPharma., a Sobi Company: Research Funding; Mays Cancer Center: Research Funding; NCI: Research Funding; LaJolla Pharma: Consultancy; Constellation: Consultancy, Research Funding; Sierra Onc: Consultancy; Novartis: Consultancy.
Raajit K. Rampal, MD, PhD, Memorial Sloan Kettering Cancer Institute and Angela G. Fleischman, MD, PhD, University of California, Irvine
Rampal: Stemline: Research Funding; Karyopharm: Consultancy; Zentalis: Research Funding; Incyte: Research Funding; CTI BioPharma Corp: Consultancy; Celgene-BMS: Consultancy; GSK-Sierra: Consultancy; Constellation: Research Funding; Zentalis: Consultancy; Servier: Consultancy; Kartos: Consultancy; Dainippon: Consultancy; Sumitomo: Consultancy; Morphosys/Constellation: Consultancy; Galecto: Consultancy; Pharmaessentia: Consultancy; Incyte: Consultancy; Ryvu: Research Funding. Fleischman: GSK, Incyte, CTI: Consultancy; Pharmaessentia, CTI: Speakers Bureau.
On Demand program will be available here January 8, 2024.

Three experts will engage in a case-based discussion of clinical data, real-world experience, and optimal management strategies for the treatment of higher-risk MF. Patient cases will be introduced and revisited throughout the program to illustrate how experts interpret and apply the latest clinical data to various case scenarios. Discussion will center around the importance of ongoing prognostic risk stratification and symptom assessment; considerations in treatment selection and sequencing, including optimizing dosage, assessing treatment resistance or intolerance, and determining when and how to switch therapies; prevention and mitigation of adverse events; and the role of allogeneic transplant and clinical trials. Learners will be prompted to share their thoughts throughout the program in audience polls and the faculty will conclude with an interactive Q&A session.